Peripheral Arterial Disease and Critical Limb Ischemia
Biogencell Ltd. is focused on clinical research in peripheral arterial disease and critical limb ischemia, particularly in patients with advanced limb ischemia who remain symptomatic despite standard pharmacological management and control of cardiovascular risk factors.
- Peripheral arterial disease (PAD)
- Critical limb ischemia (CLI)
- Chronic limb-threatening ischemia (CLTI)
The sponsor’s research interest includes patients with persistent microvascular disease after prior revascularization and those without remaining options for further revascularization treatment.
Refractory Limb Ischemia
The clinical focus extends to severe lower-extremity ischemia in individuals who have not responded adequately to standard care, with attention to cases where tissue perfusion remains compromised despite previous intervention.
- Non-responsive PAD
- Persistent microvasculature impairment
- No-option limb ischemia
Research activity is centered on therapeutic needs in advanced vascular disease affecting limb preservation and symptom burden.
Cell-Based Vascular Therapy
Biogencell Ltd. also investigates cell-based therapy for vascular restoration, with interest in approaches designed to address impaired blood flow in ischemic limbs.
- Endothelial progenitor cell therapy
- Vascular regeneration
- Microcirculatory repair
This area reflects a therapeutic emphasis on restoring circulation in patients with advanced peripheral vascular disease.
Lower-Limb Salvage
Research interests include limb salvage in patients with advanced ischemic disease, where the clinical challenge is preventing progression of tissue damage in the setting of severe arterial insufficiency.
- Ischemic limb preservation
- Tissue perfusion improvement
- Advanced arterial insufficiency
The sponsor’s work is concentrated on therapeutic options for patients with limited procedural alternatives and ongoing risk of limb loss.
